Vitrolife launch a new generation of Growth Factors and Cytokines for cultivation of stem cells
The world’s first biorisk-free growth factors and cytokines products. Manufactured in barley grain, the products are xeno-free, serum-free, endotoxin-free and present a new option for stem cell cultivation.
Through the signing of a Distribution and Supply Agreement, Vitrolife secures worldwide rights to distribute, market and sell the Growth factors and Cytokines produced in plants by ORF Genetics for cell culture media. These new products are the world’s first biorisk-free growth factors and cytokines. Manufactured in barley grain, the products are xeno-free, serum-free, endotoxin-free and present a new option for stem cell cultivation.
“Patient safety is with us all the way - from development to the final product, says Anna Mårtensson, Head of the Stem Cell business area at Vitrolife. By using barley grain and bypassing the use of bacterial or animal systems these products are contributing to a higher patient safety and in addition, the stem cell therapy companies can enjoy an easier regulatory clearance. These new growth factors and cytokines are therefore fully in-line with our focus on providing researchers and cell therapy companies high quality media, reagents and instruments that will facilitate their use of stem cells for therapeutic purposes.”
October 1, 2010
Gothenburg
Magnus Nilsson
CEO
Queries should be addressed to:
Magnus Nilsson, CEO, phone +46 31 721 80 61
Anne-Lie Sveder, CFO, phone +46 31 721 80 13
________________________________________________________________________________________________________________________________ Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes. Vitrolife today has approximately 180 employees and the company’s products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy, United Kingdom and Japan. Production facilities are housed in Sweden and USA. The Vitrolife share is listed on NASDAQ OMX Nordic Exchange, Small Cap. ________________________________________________________________________________________________________________________________ Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Tags: